Clinical trials: Chagas Disease
- Condition Chagas Disease
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Infectious Diseases
Specificity Study of Diagnostic for Chagas Disease
This study assesses the specificity of Chagas Detect™ Plus (CDP) rapid test versus standard reference tests (e.g. RIPA or IFA) for Chagas diagnosis in the US.
- Trial name
- NCT02544139
- Testing
- Chagas Detect Plus
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- InBios International, Inc.
Visceral Leishmaniasis, Chagas Disease
A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects
The purpose of this first-in-human study is to generate the necessary safety, tolerability, and pharmacokinetics (PK) information that will support further clinical development of LXE408 for the treatment of patients with…
- Trial name
- NCT07809919
- Testing
- LXE408, Iohexol
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chagas Disease
Abbott ESA Chagas Assay Post-Market Study
The study is conducted to meet an FDA post market commitment to collect and report data on the performance of the ESA Chagas assay.
- Trial name
- ESA (NCT01662362)
- Testing
- Testing Donor Specimens with ESA Chagas
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Abbott Diagnostics Division
Healthy Volunteers
First-in-Human Trial of Oral AN2-502998
First-in-Human Phase 1, Single-Center, Randomized, Blinded, Placebo-Controlled Trial in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Oral AN2-502998
- Trial name
- NCT07024589
- Testing
- AN2-502998
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AN2 Therapeutics, Inc